Compare Stocks: ADAG, LXRX, IMMX, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.85 -2.7%	$3.57	$1.30 ▼ $4.85	$188.25M	0.54	261,138 shs	297,966 shs
AVTX Avalo Therapeutics	$14.99 +0.3%	$18.17	$12.51 ▼ $24.27	$803.91M	0.68	1.15 million shs	948,502 shs
IMMX Immix Biopharma	$9.68 -5.4%	$11.71	$1.99 ▼ $15.10	$692.50M	0.24	1.66 million shs	2.55 million shs
LXRX Lexicon Pharmaceuticals	$1.82	$2.20	$1.10 ▼ $2.68	$809.82M	1.07	3.23 million shs	2.32 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-2.73%	-22.76%	-36.24%	+42.50%
AVTX Avalo Therapeutics	0.00%	-3.10%	-21.11%	-20.44%	+15.66%
IMMX Immix Biopharma	0.00%	-11.76%	-30.01%	-6.38%	+365.38%
LXRX Lexicon Pharmaceuticals	0.00%	+1.39%	-19.47%	-21.55%	+29.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.85 -2.7%	$3.57	$1.30 ▼ $4.85	$188.25M	0.54	261,138 shs	297,966 shs
AVTX Avalo Therapeutics	$14.99 +0.3%	$18.17	$12.51 ▼ $24.27	$803.91M	0.68	1.15 million shs	948,502 shs
IMMX Immix Biopharma	$9.68 -5.4%	$11.71	$1.99 ▼ $15.10	$692.50M	0.24	1.66 million shs	2.55 million shs
LXRX Lexicon Pharmaceuticals	$1.82	$2.20	$1.10 ▼ $2.68	$809.82M	1.07	3.23 million shs	2.32 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-2.73%	-22.76%	-36.24%	+42.50%
AVTX Avalo Therapeutics	0.00%	-3.10%	-21.11%	-20.44%	+15.66%
IMMX Immix Biopharma	0.00%	-11.76%	-30.01%	-6.38%	+365.38%
LXRX Lexicon Pharmaceuticals	0.00%	+1.39%	-19.47%	-21.55%	+29.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.67	204.09% Upside
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	200.87% Upside
IMMX Immix Biopharma	2.78	Moderate Buy	$24.14	149.41% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$5.70	213.19% Upside

Current Analyst Ratings Breakdown

Latest ADAG, LXRX, IMMX, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/29/2026	IMMX Immix Biopharma	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $30.00
9/28/2026	LXRX Lexicon Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IMMX Immix Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $26.00
9/14/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/10/2026	ADAG Adagene	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/14/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	IMMX Immix Biopharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $19.00
8/10/2026	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$7.67M	24.54	N/A	N/A	$0.75 per share	3.80
AVTX Avalo Therapeutics	$60K	13,398.56	N/A	N/A	$4.49 per share	3.34
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	16.26	N/A	N/A	$0.30 per share	6.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)

Latest ADAG, LXRX, IMMX, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	N/A
AVTX Avalo Therapeutics	N/A	19.31	19.31
IMMX Immix Biopharma	N/A	25.13	25.13
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
AVTX Avalo Therapeutics	87.06%
IMMX Immix Biopharma	11.26%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
AVTX Avalo Therapeutics	4.46%
IMMX Immix Biopharma	30.30%
LXRX Lexicon Pharmaceuticals	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
IMMX Immix Biopharma	21	71.54 million	49.86 million	Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable

ADAG, LXRX, IMMX, and AVTX Headlines

Recent News About These Companies

Lexicon Pharmaceuticals consensus price target increased by 17.91% to $4.64

October 2 at 12:06 PM | msn.com

Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress

October 2 at 12:06 PM | finance.yahoo.com

Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

September 30, 2026 | seekingalpha.com

Lexicon Pharmaceuticals bondit après une initiation favorable de Cantor Fitzgerald

September 29, 2026 | fr.finance.yahoo.com

Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy

September 28, 2026 | seekingalpha.com

Aktien von Lexicon Pharmaceuticals steigen nach Aufnahme der Beobachtung durch Cantor Fitzgerald mit Overweight-Einstufung

September 28, 2026 | de.marketscreener.comD

Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating

September 28, 2026 | marketscreener.comM

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

September 28, 2026 | fool.com

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

September 28, 2026 | fool.com

Lexicon Pharmaceuticals stijgt fors nu Cantor Fitzgerald onbelemmerde weg ziet bij HCM

September 28, 2026 | nl.investing.com

Saham Lexicon Pharmaceuticals melonjak usai Cantor Fitzgerald beri prospek cerah di HCM

September 28, 2026 | id.investing.com

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

September 28, 2026 | ca.finance.yahoo.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up - What's Next?

September 28, 2026 | marketbeat.com

Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target

September 28, 2026 | marketscreener.comM

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Has Average Target Price of $5.70

September 28, 2026 | americanbankingnews.com

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Hold" from Brokerages

September 28, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Picked Up by Analysts at Cantor Fitzgerald

September 28, 2026 | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at Cantor Fitzgerald

September 28, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 7.5% - What's Next?

September 24, 2026 | marketbeat.com

Lexicon Pharmaceuticals stock trades near its yearly low

September 23, 2026 | ad-hoc-news.deA

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

September 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, LXRX, IMMX, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

$2.85 -0.08 (-2.73%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.85 +0.00 (+0.07%)

As of 10/2/2026 07:30 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Avalo Therapeutics NASDAQ:AVTX

$14.99 +0.04 (+0.27%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$15.00 +0.00 (+0.03%)

As of 10/2/2026 07:30 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Immix Biopharma NASDAQ:IMMX

$9.68 -0.55 (-5.38%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.74 +0.05 (+0.57%)

As of 10/2/2026 07:31 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.82 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.01 (+0.82%)

As of 10/2/2026 07:30 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, LXRX, IMMX, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, LXRX, IMMX, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, LXRX, IMMX, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, LXRX, IMMX, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

Avalo Therapeutics NASDAQ:AVTX

Immix Biopharma NASDAQ:IMMX

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAG, LXRX, IMMX, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAG, LXRX, IMMX, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAG, LXRX, IMMX, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, LXRX, IMMX, and AVTX Company Descriptions

Adagene NASDAQ:ADAG

Avalo Therapeutics NASDAQ:AVTX

Immix Biopharma NASDAQ:IMMX

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools